Following a full submission
AWMSG advice |
||
| Status: Recommended | ||
Enoxaparin (Clexane®) is recommended as an option for use within NHS Wales for the treatment of acute ST-segment elevation myocardial infarction (STEMI). AWMSG is of the opinion that enoxaparin (Clexane®) is not suitable for shared care within NHS Wales. |
||
|
||
Medicine details |
||
| Medicine name | enoxaparin (Clexane®) | |
| Formulation | solution for injection | |
| Reference number | 125 | |
| Indication | Treatment of acute ST-segment elevation myocardial infarction (STEMI) |
|
| Company | Sanofi-Aventis Ltd | |
| BNF chapter | Cardiovascular system | |
| Submission type | Full | |
| Status | Recommended | |
| Advice number | 0610 | |
| NMG meeting date | 17/03/2010 | |
| AWMSG meeting date | 28/04/2010 | |
| Ratification by Welsh Government | 28/05/2010 | |
| Date of issue | 01/06/2010 | |